INSM stock forecast
Our latest prediction for Insmed, Inc.'s stock price was made on the March 1, 2017 when the stock price was at 16.47$.
In the short term (2weeks), INSM's stock price should underperform the market by -0.46%. During that period the price should oscillate between -8.36% and +9.57%.
In the medium term (3months), INSM's stock price should outperform the market by 2.62%. During that period the price should oscillate between -19.04% and +25.95%.Get email alerts
About Insmed, Inc.
Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -3.91$ per share.
The book value per share is 4.80$
Three months stock forecastMarch 1, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|